23andMe Holding Co. (OQ:ME)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 349 Oyster Point Boulevard
Tel: N/A
Website: https://investors.23andme.com
IR: See website
Key People
Anne Wojcicki
Chief Executive Officer, Director
Paul Johnson
Chief Operating Officer - Consumer
Steve Schoch
Chief Accounting Officer
Kathy L. Hibbs
Chief Administrative Officer, Company Secretary
Kenneth J. Hillan
Chief Therapeutics Officer
Business Overview
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients' lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Financial Overview
For the fiscal year ended 31 March 2023, 23andMe Holding Co. revenues increased 10% to $299.5M. Net loss increased 43% to $311.7M. Revenues reflect Telehealth segment increase from $19.2M to $44.7M, Research services segment increase of 5% to $52.4M, United States segment increase of 13% to $217.2M, United Kingdom segment increase of 8% to $63M.
Employees: 769 as of Mar 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $558.72M as of Mar 31, 2023
Annual revenue (TTM): $299.49M as of Mar 31, 2023
EBITDA (TTM): -$276.74M as of Mar 31, 2023
Net annual income (TTM): -$311.66M as of Mar 31, 2023
Free cash flow (TTM): -$176.70M as of Mar 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 461,255,005 as of May 18, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.